BD 2132275 - PowerLoc Max Safety Infusion Set with Y-Site, 22G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

BD 2132275 - PowerLoc Max Safety Infusion Set with Y-Site, 22G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

The BD 132275 PowerLoc Max Safety Infusion Set is a power-injectable port-access device designed for accessing compatible surgically implanted vascular ports. The set features a 22-gauge non-coring needle with a 0.75-inch length and an integrated Y-injection site, providing primary and secondary access options for compatible infusion therapy, blood sampling, implanted port maintenance, and diagnostic imaging procedures.

The 22-gauge configuration provides a smaller needle profile than 19-gauge and 20-gauge PowerLoc Max options while retaining power-injection capability for appropriately rated vascular-access systems. BD technical documentation specifies a maximum power-injection flow rate of 2 mL per second for 22-gauge PowerLoc Max infusion sets.

The 0.75-inch needle length is designed for implanted ports positioned relatively close to the skin surface. Correct needle-length selection helps support complete septum access, stable positioning, secure dressing application, and reliable therapy delivery.

The integrated Y-injection site provides an additional access point within the fluid pathway for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway. BD documentation lists an approximate priming volume of 0.4 mL for PowerLoc Max configurations equipped with a Y-site.

The PowerLoc Max platform incorporates a compact, wingless design with a clear plastic base, non-absorbent padded footprint, and safety technology intended to support patient comfort, access-site visibility, dressing management, and clinician protection.

An integrated single-step safety mechanism is designed to cover and secure the needle point during deaccessing. An audible click helps indicate activation, supporting safer handling and helping reduce the risk of accidental needlestick exposure.

BD 132275 corresponds to manufacturer catalog number 0132275 and is supplied in a 25-unit shelfpack or commercial pack configuration.

Key Benefits

• 22-gauge non-coring needle supports access to compatible surgically implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial implanted ports.
• Smaller 22-gauge profile provides an option when a finer access needle meets prescribed therapy requirements.
• Power-injectable design supports compatible contrast-enhanced diagnostic imaging procedures.
• Maximum power-injection flow rate of 2 mL per second for 22-gauge PowerLoc Max configurations.
• Minimum gravity flow rate of approximately 312 mL per hour under specified test conditions.
• Integrated Y-injection site provides secondary access for compatible medication, flushing, or fluid administration.
• Approximate 0.4 mL priming volume supports fluid-management planning.
• Non-coring needle design helps minimize unnecessary damage to compatible implanted port septa during appropriate access.
• Single-step safety activation simplifies needle protection during deaccessing.
• Needle-point coverage with an audible click helps indicate safety activation.
• Clear plastic base supports ongoing visualization of the insertion site.
• Compact footprint helps facilitate dressing application and site care.
• Wingless design supports a streamlined dressing profile.
• Non-absorbent padded base is designed to support patient comfort.
• Rotating needle hub supports maneuvering and positioning of tubing.
• Dual-lumen port compatibility supports appropriate implanted port applications.
• Integrated safety mechanism helps reduce accidental needlestick exposure during removal, transport, and disposal.
• 25-unit packaging supports hospital, oncology, infusion, and diagnostic imaging inventory management.

Compatibility and Applications

The BD 132275 PowerLoc Max Safety Infusion Set is intended for use with compatible surgically implanted vascular-access ports designed to accept non-coring port-access needles.

Potential clinical applications include chemotherapy administration, antibiotic therapy, hydration, compatible nutritional therapy, blood product administration, long-term infusion therapy, blood specimen collection, implanted port flushing, and compatible contrast-media injection during diagnostic imaging procedures.

The 22-gauge configuration may be selected when a smaller needle profile is appropriate for the implanted port and prescribed therapy. Selection should consider medication or fluid characteristics, required flow rate, implanted port specifications, patient anatomy, imaging requirements, and professional clinical judgment.

The 0.75-inch needle length is generally appropriate for implanted ports located relatively close to the skin surface. A needle that is too short may not fully access the port septum, while unnecessary additional needle length may affect stability, securement, dressing placement, and patient comfort.

The integrated Y-injection site provides secondary access within the fluid pathway and may support compatible intermittent medication administration, flushing, or connection of another approved fluid pathway when permitted by the prescribed therapy and institutional protocol.

The PowerLoc Max platform is compatible with appropriate dual-lumen implanted port applications. Exact compatibility should be verified with the implanted port model, prescribed therapy, and facility procedures before use.

For power injection, the implanted port, PowerLoc Max needle, Y-injection site, tubing, connectors, extension components, and every other component within the complete fluid pathway must be appropriately rated for the intended procedure.

The lowest-rated component in the complete vascular-access system determines the actual maximum allowable operating pressure and flow rate. For the 22-gauge PowerLoc Max configuration, manufacturer technical documentation specifies a maximum power-injection flow rate of 2 mL per second.

Usage Guidelines

The BD 132275 should be used only by healthcare professionals trained and authorized to access surgically implanted vascular ports. Current manufacturer instructions, institutional protocols, aseptic technique, and implanted port instructions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status when applicable.
• Assess the implanted port location and tissue depth before selecting the 0.75-inch needle.
• Verify that a 22-gauge needle provides appropriate flow capability for the intended therapy or imaging procedure.
• Confirm that the integrated Y-injection site is appropriate for the planned clinical workflow.
• Inspect the package for damage, punctures, moisture, contamination, expiration, or compromised integrity.
• Prepare the implanted port site using appropriate skin-antisepsis and sterile-access procedures.
• Prime the primary fluid pathway and any intended secondary pathway with an approved solution.
• Remove air completely from the fluid pathway before accessing the implanted vascular port.
• Position the tubing and rotating hub appropriately for access and dressing application.
• Stabilize the implanted port and insert the non-coring needle using the approved technique.
• Advance the needle carefully until appropriate access to the port reservoir is achieved.
• Verify correct needle placement according to institutional protocol, including blood-return assessment when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility policy.
• Secure the PowerLoc Max base and tubing to minimize pulling, twisting, pressure, or displacement.
• Apply an appropriate sterile dressing while maintaining access-site visibility.
• Disinfect the Y-injection site before each access according to institutional infection-prevention procedures.
• Maintain aseptic technique whenever connecting to or manipulating the Y-site.
• Monitor the access site for pain, swelling, redness, leakage, displacement, or other abnormalities throughout therapy.
• Confirm power-injection eligibility before connecting the system to a power injector.
• Do not exceed 2 mL per second or the lower operating limit of another component within the complete vascular-access system.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the implanted port during needle withdrawal and activate the safety mechanism according to manufacturer instructions.
• Confirm that the needle point is completely protected before further handling.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the vascular-access system if unexpected resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, displacement, or another abnormality develops at the implanted port site.

Certifications and Safety Standards

The BD 132275 PowerLoc Max Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The integrated safety mechanism is designed for smooth, single-step activation during deaccessing. Once activated, the mechanism covers the needle point, while an audible click helps provide confirmation of safety activation.

This built-in safety technology is designed to help reduce the risk of needlestick injury and potential exposure to bloodborne pathogens during needle removal, transport, and disposal.

The clear plastic base allows clinicians to maintain visibility of the insertion site throughout therapy, supporting routine assessment for redness, swelling, leakage, displacement, or other changes.

The wingless design and non-absorbent padded base are intended to support dressing application and patient comfort while maintaining a compact footprint over the implanted port.

Safety technology does not replace appropriate clinician training, personal protective equipment, aseptic technique, safe sharps-handling procedures, exposure-control practices, or immediate disposal in an approved sharps container.

Healthcare organizations should verify current manufacturer documentation for applicable FDA status, UDI information, sterilization details, material composition, natural rubber latex information, DEHP information, shelf life, storage requirements, warnings, precautions, contraindications, and other product-specific requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety technology, the PowerLoc Max platform incorporates a built-in mechanism designed to cover and secure the needle point during deaccessing, helping reduce accidental sharps exposure.

Compared with PowerLoc Max configurations without a Y-injection site, BD 132275 provides an integrated secondary access point. This may support compatible intermittent medication administration, flushing, or connection of another approved fluid pathway without disconnecting the primary line.

Compared with standard PowerLoc safety infusion sets, the PowerLoc Max platform features a compact wingless footprint, clear base, non-absorbent padded platform, rotating hub, and single-step safety activation designed to support dressing management, patient comfort, and clinician protection.

Compared with 19-gauge and 20-gauge PowerLoc Max configurations, the 22-gauge needle provides a smaller needle profile but has a lower manufacturer-specified maximum power-injection flow rate.

Compatible 19-gauge and 20-gauge PowerLoc Max configurations are rated for power injection up to 5 mL per second, while 22-gauge PowerLoc Max configurations are rated up to 2 mL per second according to BD technical documentation.

Compared with non-power-injectable Huber needles, BD 132275 provides power-injection capability when used with a fully compatible implanted port and vascular-access pathway within the specified operating limits.

Compared with 1-inch and 1.5-inch PowerLoc Max needles, the 0.75-inch configuration provides a shorter access length for implanted ports positioned closer to the skin surface.

Alternative safety infusion sets may vary in gauge, needle length, priming volume, Y-site availability, power-injection capability, safety activation method, base design, and package quantity. BD 132275 combines a 22-gauge, 0.75-inch non-coring needle with an integrated Y-injection site, 0.4 mL priming volume, compact wingless padded base, clear site-viewing platform, rotating hub, integrated safety technology, and power-injection capability up to 2 mL per second.

Typical User Profile and Application Scenarios

The BD 132275 PowerLoc Max Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing surgically implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other appropriately qualified healthcare personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port can be appropriately accessed with a 0.75-inch needle and whose prescribed therapy or diagnostic procedure is compatible with a 22-gauge access device.

Typical applications may include chemotherapy administration, antibiotic infusion, hydration, compatible nutritional therapy, blood specimen collection, implanted port flushing, routine port maintenance, and compatible contrast-enhanced imaging procedures within the product's specified flow limitations.

The integrated Y-site is particularly useful in clinical workflows requiring secondary access for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway.

Best Practices for Use and Maintenance

The BD 132275 is a port-access device intended for professional clinical use. Best practices focus on accurate product selection, sterile preparation, appropriate needle-length assessment, Y-site management, flow-rate verification, access-site monitoring, safety activation, and proper disposal.

• Verify BD 132275 or manufacturer catalog number 0132275 before opening the package.
• Confirm the 22-gauge size, 0.75-inch needle length, and integrated Y-injection site configuration.
• Inspect package integrity and expiration information before use.
• Assess patient tissue depth and implanted port position before selecting the 0.75-inch needle.
• Confirm that the prescribed therapy and required flow characteristics are appropriate for a 22-gauge access device.
• Use strict aseptic technique throughout preparation, priming, insertion, connection, dressing, and deaccessing.
• Prime the complete primary and intended secondary fluid pathways before implanted port access.
• Consider the approximately 0.4 mL priming volume when precise fluid management is clinically important.
• Use the rotating hub to position the tubing appropriately for dressing and site management.
• Maintain the padded base in a stable position throughout therapy.
• Use the clear base to support routine visual assessment of the insertion site.
• Disinfect the Y-injection site according to institutional protocol before every access.
• Protect unused access points from contamination.
• Monitor the implanted port site and all tubing connections regularly.
• Verify that the complete vascular-access system is power injectable before any power-injection procedure.
• Follow the 2 mL per second maximum power-injection rating specified for 22-gauge PowerLoc Max configurations in BD technical documentation.
• Always follow the lowest pressure or flow limitation of any component within the complete system.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Follow current manufacturer instructions regarding single-use handling and disposal.
• Confirm complete safety activation immediately following needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 132275 PowerLoc Max Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

BD identifies manufacturer catalog number 0132275 as the PowerLoc Max Power-Injectable Infusion Set with Y-Injection Site, 22G x 0.75-inch.

BD technical documentation for the PowerLoc Max family specifies a maximum power-injection flow rate of 2 mL per second for 22-gauge configurations, a minimum gravity flow rate of approximately 312 mL per hour under specified conditions, and an approximate priming volume of 0.4 mL for configurations with a Y-site.

Before use, verify the product identity, 22-gauge size, 0.75-inch needle length, Y-site configuration, package integrity, expiration date, and compatibility with the implanted vascular port.

The set should not be used for power injection unless the implanted port and every component within the complete fluid pathway are specifically rated for the intended procedure. Permitted pressure, flow rate, contrast-media characteristics, and other operating conditions must be confirmed before use.

The lowest-rated component within the complete vascular-access system determines the actual maximum allowable operating limit. Healthcare professionals should follow current manufacturer labeling and the applicable PowerLoc Max technical documentation when determining allowable power-injection parameters.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may contribute to infiltration, extravasation, leakage, tissue injury, implanted port damage, interrupted therapy, or other complications.

The Y-injection site should be accessed only with compatible devices using appropriate disinfection and aseptic technique. Inadequate disinfection or improper manipulation may increase the risk of contamination, connection problems, or bloodstream infection.

The integrated safety mechanism should be fully activated according to current manufacturer instructions following port deaccessing. The used device remains a contaminated sharp and should be discarded immediately in an approved sharps container.

BD lists manufacturer SKU 0132275 as 25 units per shelfpack with a minimum order quantity of one shelfpack. CIA Medical lists BD 132275 as a 25-per-pack commercial configuration. Purchasing personnel should confirm current availability, selling unit, storage requirements, and ordering information before procurement.

How to Order

Select the BD 132275 - PowerLoc Max Safety Infusion Set, 22G x 0.75", Y-Site and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.